Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved - Seite 2

The shareholders granted discharge to all members of the Board of Directors and of the Executive Management and re-elected all members of the Board which stood for election for a term of office until the conclusion of the AGM 2016. Mr. Carl Feldbaum and Mr. Werner Henrich did not stand for re-election.

The shareholders elected Ms. Herna Verhagen and Mr David Stout as new Board members for a term of office until the conclusion of the AGM 2016.

In addition, the shareholders elected Mr. Jean-Pierre Garnier as Chairperson of the Board and Ms. Herna Verhagen, Mr. Jean-Pierre Garnier, and Mr. John J. Greisch (Chair) to the Compensation Committee.

Following the AGM, the Board of Directors of Actelion comprises a total of 10 members: Jean-Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel, John J. Greisch, Peter Gruss, Michael Jacobi, Jean Malo, David Stout and Herna Verhagen.

Jean-Pierre Garnier, concluded: "During their long service as integral members on the Board of Directors, both Carl Feldbaum and Werner Henrich have supported Actelion to become the successful global player it is today. I would like to thank both gentlemen for their contributions, Actelion has greatly benefitted from the experience they brought to the table. I would also like to welcome Herna Verhagen and David Stout as new members of the Board of Directors. Both bring significant experience to Actelion, and I look forward to working with them."

BDO AG, represented by Mr. Marc Schaffner, was elected as Independent Proxy for a term of office until the conclusion of the AGM 2016.

Ernst & Young was re-elected as the company's statutory auditors for the business year 2015.

###

NOTES TO THE EDITOR

ABOUT ACTELION LTD.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.